In this issue:
- Patients’ views on ctDNA monitoring in early-stage melanoma
- ‘Rainbow pattern’: a dermoscopic sign of invasive melanoma
- Adjuvant pembrolizumab in completely resected stage IIB–IIC melanoma
- Global burden of melanoma in 2020, and projections to 2040
- MAPKinase inhibition after ICI failure in advanced melanoma
- Primary-care screening initiative for melanoma
- Adaptive nivolumab + ipilimumab dosing in advanced melanoma
- MCC recurrence and mortality risk by stage and time since diagnosis
- Predicting response/survival to anti-PD-1 ±ipilimumab in metastatic melanoma
Please login below to download this issue (PDF)